Last reviewed · How we verify
NCT04125290: PROXY
US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)
trial in Hairy Cell Leukemia in 2 participants. Terminated before completion.
21 June 2021
Quick facts
| Lead sponsor | AstraZeneca |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 2 |
| Start date | 9 December 2019 |
| Primary completion | 21 June 2021 |
| Estimated completion | 21 June 2021 |
| Sites | 2 locations across United States |
Conditions studied
- Hairy Cell Leukemia — all drugs for Hairy Cell Leukemia →
Sponsor
AstraZeneca — full company profile →
Who can join
Eligibility, any sex, with Hairy Cell Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is being conducted to satisfy a post-marketing requirement (PMR) to provide evidence characterizing 1) the safety of moxetumomab pasudotox-tdfk in patients who are 65 years of age and older and/or 2) the safety of moxetumomab pasudotox-tdfk in patients who have moderate renal impairment defined as an estimated GFR of 30-59 ml/min
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside.
Alfaleh MA, Alsaab HO, Mahmoud AB, Alkayyal AA, et al · · 2020 · cited 194× · PMID 32983137 · DOI 10.3389/fimmu.2020.01986 -
The protective role of the microenvironment in hairy cell leukemia treatment: Facts and perspectives.
Gargiulo E, Giordano M, Niemann CU, Moussay E, et al · · 2023 · cited 2× · PMID 36968995 · DOI 10.3389/fonc.2023.1122699
Verify or expand the search:
- PubMed search for NCT04125290
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hairy Cell Leukemia
Currently open trials in the same condition.
- NCT06965114 — Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia · Phase 1, PHASE2 · recruiting
- NCT06561360 — A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL) · Phase 2 · recruiting
- NCT04815356 — Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Varian · Phase 1 · recruiting
- NCT05388123 — Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia · Phase 2 · active not recruiting
- NCT04775745 — Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. · Phase 1 · recruiting
Other AstraZeneca trials
Trials by the same sponsor.
- NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
- NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
- NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
- NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
- NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04125290 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
- Last refreshed: 18 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04125290.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing